Intech Investment Management LLC Makes New $191,000 Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

Intech Investment Management LLC purchased a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 25,522 shares of the company’s stock, valued at approximately $191,000.

Several other large investors have also made changes to their positions in the company. Innealta Capital LLC acquired a new stake in Vir Biotechnology in the second quarter valued at approximately $32,000. Blue Trust Inc. lifted its stake in shares of Vir Biotechnology by 143.5% in the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares during the last quarter. nVerses Capital LLC bought a new stake in Vir Biotechnology in the third quarter worth $56,000. Magnetar Financial LLC bought a new stake in Vir Biotechnology in the second quarter worth $95,000. Finally, Quest Partners LLC increased its position in Vir Biotechnology by 142.1% during the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock worth $113,000 after buying an additional 7,452 shares during the last quarter. Institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on VIR shares. Barclays reduced their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Stock Up 4.8 %

Shares of NASDAQ VIR opened at $8.35 on Friday. Vir Biotechnology, Inc. has a 12 month low of $6.56 and a 12 month high of $13.09. The company has a market cap of $1.15 billion, a P/E ratio of -2.03 and a beta of 0.49. The business’s 50 day moving average is $7.98 and its two-hundred day moving average is $8.76.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. During the same period last year, the firm posted ($1.22) EPS. The company’s revenue was down 9.8% compared to the same quarter last year. Sell-side analysts expect that Vir Biotechnology, Inc. will post -3.36 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the sale, the director now directly owns 11,616 shares in the company, valued at approximately $90,604.80. The trade was a 51.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders sold 16,016 shares of company stock valued at $128,034. Insiders own 15.60% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).